UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2025 P 1318-6
Program Prior Authorization/Notification
Medication Isturisa® (osilodrostat)
P&T Approval Date 6/2020, 6/2021, 6/2022, 6/2023, 6/2024, 6/2025
Effective Date 9/1/2025
1. Background:
Isturisa (osilodrostat) is a cortisol synthesis inhibitor indicated for the treatment of endogenous
hypercortisolemia in adults with Cushing’s syndrome for whom surgery is not an option or has
not been curative.
2. Coverage Criteriaa:
A. Initial Authorization
1. Isturisa will be approved based on both of the following criteria:
a. Diagnosis of Cushing’s syndrome
-AND-
b. One of the following:
(1) Patient is not a candidate for pituitary surgery
-OR-
(2) Pituitary surgery has not been curative
Authorization will be issued for 12 months.
B. Reauthorization
1. Isturisa will be approved based on the following criterion:
a. Documentation of positive response to Isturisa therapy
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
© 2025 UnitedHealthcare Services, Inc.
1
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-
authorization based solely on previous claim/medication history, diagnosis codes (ICD-10)
and/or claim logic. Use of automated approval and re-approval processes varies by program
and/or therapeutic class.
• Supply Limits may be in place
4. References:
1. Isturisa [Package Insert]. Bridgewater, NJ: Recordati Rare Disease, Inc.; April 2053.
Program Prior Authorization/Notification - Isturisa (osilodrostat)
Change Control
6/2020 New program
6/2021 Annual review with no change to coverage criteria.
6/2022 Annual review with no change to clinical criteria.
6/2023 Annual review with no change to coverage criteria. Added state
mandate footnote.
6/2024 Annual review with no change to coverage criteria. Updated reference.
6/2025 Annual review. Updated nomenclature with no change to clinical
intent. Update background and reference.
© 2025 UnitedHealthcare Services, Inc.
2